Nothing said here yet.
to join the conversation.
| Inglis Tiffany Eul DavisChief Medical Officer | Sell | 8,024 | $16.3K | Mon, Oct 12 |
| Lindgardt ZhenyaChief Executive Officer | Sell | 7,022 | $14.0K | Thu, Sep 10 |
| Jackson BenjaminGeneral Counsel | Sell | 2,190 | $4.4K | Thu, Sep 10 |
| Anderson Dyaarl Lee Jr.Chief Commercial Officer | Sell | 1,800 | $3.6K | Thu, Sep 10 |
| Inglis Tiffany Eul DavisChief Medical Officer | Sell | 486 | $972 | Thu, Sep 10 |
| Lindgardt ZhenyaChief Executive Officer | Sell | 20,139 | $40.3K | Tue, Sep 8 |
En partenariat avec l'ADAA, l'initiative « I'M FINE » encourage les femmes à faire le point sur leur bien-être mental et à repérer les premiers signes d'anxiété et de dépression. PARIS, 8 octobre 2026 /PRNewswire/ -- « Comment allez-vous ?
Illinois Medicaid coverage for PreTRM test unlocks 50,000 annual births as payer access expands.
SALT LAKE CITY, Aug.
Despite minimal revenue, Sera Prognostics advances commercial strategy with new payer programs and a strengthened cash runway through 2029.
Sera Prognostics (SERA) delivered earnings and revenue surprises of -28.57% and -76.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter ended…
Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report second quarter fiscal year 2026 financial results on Wednesday August 12, 2026, after the close of the market.